NCT00977210 - Safety Study of OXi4503 (a Vascular Disrupting Agent) Given by 3 x Weekly Intravenous Infusions to Patients With Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2005

Primary Completion Date

September 30, 2010

Conditions

Solid Tumors

Interventions

DRUG

OXi4503

OXi4503 will be administered weekly for 3 weeks followed by a week with no treatment. The starting dose will be 0.06 mg/m2 given as an intravenous infusion over 10 minutes.

Trial Locations (2)

Unknown

CRUK Investigational Site, Manchester

CRUK Investigational Site, Middlesex